The regulatory regime and its impact on innovation activities in agro-food biotechnology in the EU and USA
Since the mid 1990s genetically modified (GM) plants are marketed and cultivated which directly or via animal feed can enter the food chain. In this respect genetic engineering approaches are regarded by their protagonists as major tools to increase productivity and efficiency in food processing in future (Garza & Stover, 2003) , On the other hand, an intensive public debate is carried out globally concerning the safety of these approaches and derived novel foods as well as their socio-economic impacts (Otsuka, 2003) . Critics of genetic engineering see the potential that this technology may result in harm for the environment and human or animal health. In addition, the wider impacts of the use of genetic engineering in the agro-food sector on society as a whole are often questioned in the public debate (Menrad, Gaisser, Huesing, & Menrad, 2003) .
1
Regulatory principles in EU and USA Since GMOs and derived novel food products represent new developments in the area of food production and food processing, there have been relatively restricted experiences with this type of products. Therefore, state authorities which are generally in charge to ensure safety of consumers in relation to nutrition as well as to prevent misleading of consumers in this field took specific activities to deal with potential risks of GMOs related to human health and the environment. The general targets of the respective legislation are to ensure human health when consuming GMOs or derived novel foods, to prevent or minimise potential harm of GMOs to the environment as well as to provide the necessary information in order to ensure the freedom of choice of consumers or users of such products. In particular, the EU policy related to GMOs was intensively influenced by the emergence of the BSE and other food crises during the 1990s, the public criticism and undermined trust in public authorities to adequately manage such crises in the sensitive area of food production and food processing as well as the low consumer acceptance of agro-food biotechnology (Loureiro, 2003) .
The fundamental question which arises concerning regulation of GMOs is whether GM crops or other GMOs have to be acknowledged like conventional crops or organisms, and therefore it is sufficient to use the general legislation valid for such crops or organisms or whether it is necessary to adopt different and specific regulations for GMOs. In this context USA and EU have decided to take divergent approaches. In the USA GM crops are considered specific and different in terms of intellectual property rights since a patent can be granted to them but not to conventional crops. On the other hand, the introduction of GM crops in the environment and into the market follows the principle of "substantial equivalence" and therefore the same steps are required like for conventional crops (Esposti & Sorrentino, 2002) .
The EU takes the opposite approach concerning regulation of GMOs compared to the USA. Even after Directive 98/44/EC patents cannot be granted to GM crops. They are protected by the same breeders rights acknowledged to conventional crops, thereby giving higher priority to the "farmers rights" and "breeders privilege" than to the innovators' intellectual property rights (Esposti & Sorrentino, 2002) . In contrast to the US approach, the EU approach for environmental release and market approval of GMOs follows a rather strict interpretation of the "precautionary principle", i. e. specific regulations have been put into force dealing with GMOs which require different and often more complex procedures than for conventional products. .
Since its enpassment in the year 1990 Directive 90/220/EEC was criticised by different stakeholder groups. In addition, all notifications for market approval of agricultural GMOs raised concerns of one or several EU Member States during the 1990s (Sauter & Meyer, 2000) . Therefore, in June 1999 a de facto moratorium on commercialisation of GMOs was agreed by the Community's Council of Environmental Ministers to suspend all approval applications for GMOs until implementation of the revised Directive 90/220/EEC, in order to provide a more strict legal framework covering not only safety issues but also labelling and traceability of GMOs (Lheureux et al., 2003 approval of GMOs will be given only for a ten-years time period and can be extended for another ten years. In addition, starting with the year 2005 no commercial release of GMOs will be allowed which contains antibiotic resistance marker genes, for which harmful impacts on human health and the environment are discussed (Schütte, Stirn, & Beusmann, 2001 ).
Directive 2001/18/EC requires a post-market monitoring of each approved GMO in order to detect unanticipated effects of such organisms to the environment and human health.
Furthermore, labelling of GMOs is foreseen in this Directive without giving details concerning traceability requirements for products which contain GMOs or are derived from GMOs (Loureiro, 2003) . The same relates to tolerance levels for unadventitious mixture of GM material with non-GM crops or products .
In November Learning from the US experience with Starlink, the Regulation provides that GMOs likely to be used as food and feed can only be authorised for both purposes or not at all.
Concerning labelling of GM derived foods the Regulation extends the labelling requirements of Regulation 258/97/EC to all foods produced from GMOs, irrespectively of whether there is DNA or protein of GM origin in the final food product or the feed. This means that the use of genetic engineering approaches at any step of the food production and processing process will lead to labelling requirements even if GMOs cannot be identified in the final product (like e. g. in soybean oil). Such a system requires the establishment of a traceability system for GMOs in the food processing chain as well as the delivery of information to whom and from whom GM foods are made available . The labelling requirement will not apply for adventitious presence of GMOs approved for commercialisation in the EU below a 0.9 % threshold. Products which have not received permission to be marketed in the EU, but for which the scientific assessment is positive, will have to be labelled if the GM content exceeds 0.5 % adventitiously (Kinderlerer, 2003) .
In July 2003 the European Commission has published guidelines for developing strategies and best practices to ensure the co-existence of GM crops with conventional and organic agriculture (European Commission, 2003b) . They are intended to support Member
States to develop workable measures for co-existence in conformity with EU legislation. The guidelines set out the general principles as well as the technical and procedural aspects which should be taken into account during this process. In the guidelines it is underlined to ensure a fair balance between the interests of farmers of all types of production, i. e. farmers should be able to choose the production type they prefer. During the phase of introduction the European Commission proposed the general principle that farmers who introduce a new production type should be responsible for implementing the measures necessary to limit admixture during the phase of introduction of a new production type in a region (European Commission, 2003b) .
Impact of regulation on innovation indicators in the EU
The impact of the regulatory framework relevant for agro-food biotechnology and genetic engineering in the different regions can be analysed on various levels. In the following respective data are presented for the areas of scientific research, field trials with GMOs, approval and cultivation of GMOs in the different regions.
In the EU there is still a broad pipeline of R&D activities related to agricultural and food GMOs which is fuelled by differing organisations like large multinational companies, SMEs, universities and non-university research institutions (Lheureux et al., 2003) . In the EU a broad variety of different plants are used for genetic modification experiments, with model plants (Arabidopsis thaliana and tobacco), vegetables (including mainly potatoes and tomatoes), cereals (like e. g. maize, wheat, barley) and specific field crops (in particular oilseed rape, sugar beet) accounting for more than 80 % of all GM projects in the laboratory phase (Lheureux et al., 2003) . Other crop categories like fruits, (wood) trees, grasses or flowers are of minor importance in the EU.
So-called input agronomic traits account for 38 % of all genetic modification projects in the laboratory phase (Lheureux et al., 2003) . Resistance against herbicides, insects and other plant pathogens are investigated in 21 % of all projects. Around 13 % of all identified projects deal with abiotic stress or the improvement of yield characteristics of plants. Output traits account for 39 % of all traits with half of the projects referring to modification of specific nutrients or ingredients (Lheureux et al., 2003) . The output trait category "health-related ingredients" plays an important role as well, since it accounts for 11 % of all projects related to GM plants in the laboratory phase. 17 % of all projects are classified in the "marker/other traits" category including projects in a very early phase of the development of a GM plant (Lheureux et al., 2003) .
Another indicator for research activities in a specific area are scientific publications in reviewed journals. The analysis of publication activities in biotechnology in the EU Member States indicates a strong growth of the scientific output in biotechnology between significance of biotechnology among all scientific activities in the Member States increased during the recent decade with most European countries performing above the world average.
However, the analysis of the dynamics of specialisation patterns in biotechnology-related publications indicates that the area of plant biotechnology is the only sub-field of biotechnology research which showed significant negative growth during the second half of the 90s in the EU (figure 1). 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 Source: Lheureux et al., 2003 , Transgen, 2004 The majority of EU field trial notifications with GM plants referred to four crops: maize Commission indicates that 39 % of institutions active in agro-food biotechnology related research have cancelled R&D projects related to GMOs in the last four years (Lheureux et al., 2003) . While less than one quarter of the universities or public research institutes have cancelled GMO projects, more than half of the SMEs and two third of the large companies reported such activities (table 1). 38.8 % 60.6 % 1) One respondent answered "Don't know"
2) Other institutions are included, 3 questionnaires without an answer to this question.
Source: Lheureux et al., 2003 A broad range of different reasons was mentioned by the respondents for cancelling R&D projects related to GMOs in the agricultural field. The highest importance was given to the regulatory field (e. g. unclear legal situation in the EU, unclear or high requirements for safety testing of products), and the uncertain market situation due to low consumer and user acceptance of GM products. Between 16 % and 21 % of all respondents marked these two aspects (Lheureux et al., 2003) . In addition, a relatively high importance was given to financing and cost aspects as well as the feasibility of the planned R&D projects, while intellectual property right issues, an appropriate co-operation partner as well as experienced staff was only for a small group of respondents a reason for cancelling R&D laboratory projects related to GMOs (Lheureux et al., 2003) .
Impact of regulation on innovation indicators in the USA
Comparable data to the character of GMO-related research projects to those of the EU could not be found during literature search for USA. Therefore, the analysis for this country starts with field trials with GM plants.
In the US, over 8,400 field trials with GMOs have been registered since 1987 (figure 3). A direct comparison between the numbers of notifications in the EU and the number of notifications in the USA is not feasible due to differences in how the data is collected. Nevertheless, when taking into account the average field trial duration in the EU of 2.6 years (Lheureux et al., 2003) , it is evident that the negative trend found in annual EU notifications since 1999 does not exist to the same extent in the USA. Bayer Crop Science) accounted for 48 % of all trials and almost two thirds of the trials were carried out in maize, potato and soybean (Arundel, 2002b) . 27.5 % of the US trials related to herbicide resistance, 41.6 % to pest resistance, 19.2 % to output traits for food or industrial purpose and the remaining 11.7 % to other categories like markers, fertility and agronomic traits (Arundel, 2002a) . Among pest resistance 63 % related to insect resistance (mostly using the Bt gene), 21 % to virus resistance and around 12 % to fungi (Arundel, 2002b) .
Concerning the development over time, it can be observed that herbicide resistance had the Drug Administration (Rampton, 2004) .
Another important crop in terms of commercialised GM products is oilseed rape of which 16 varieties had been commercialised globally (Lheureux et al., 2003) . This related in particular to the USA, Japan, Australia and Canada (Lheureux et al., 2003) . The EU regulatory framework adopted during the 1990s has played an important, largely negative role for the development of GMOs in the EU in the last decade. During this time period increased regulatory oversight in agro-food biotechnology coincided with growing negative public opinion and diminished trust in public authorities and regulatory agencies. In this context companies regarded the "constantly changing regulatory environment" as one major constraint for R&D and commercialisation of GMOs in the EU. In particular the practical handling of the existing regulations was strongly criticised as being to slow, bureaucratic and causing extraordinary costs. Politics was criticised for not taking any clear decision regards GMOs (which will form a reliable planning basis for the companies) and periodically intervening in the regulatory processes.
Combining the findings of Lheureux et al. (2003) with the analysis of the performance of scientific publications in different subfields of biotechnology (Reiss & Dominguez Lacasa, 2003) provides evidence, that the unclear legal situation with respect to the commercialisation of GMOs which emerged in the second half of the 1990s led to the cutting down of research activities in plant biotechnology which can be measured as decreasing scientific output. In more general terms, the unclear legal situation related to GMO on the commercial side seems to have a negative feedback on the science base. This could give reason for concern that once the legal environment would become more stable and/or more favourable for commercialisation of GMOs, the EU knowledge base would be less prepared to provide the required know-how.
The "proof of principle" of the differing GMO-related regulatory approaches of USA and EU cannot be provided so far since no consumer or user reactions which are based on purchasing behaviour can be measured in the EU with regard to GM products. However, analyses of other innovative areas of food production and processing (e. g. Functional Food, organic agriculture and foods) indicate that even a strict, but clear regulatory framework has positive impacts on innovation parameters both in the EU and USA (Blind et al., 2003) . In this sense, politics is asked to provide such a framework for agro-food biotechnology in the EU as well while industry should accept the critical view of many consumers with respect to genetic engineering and thus develop products which offer clear and obvious benefits to consumers. In addition, these products should be marketed with clear labels in order to ensure consumers' freedom of choice.
